Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA
The result is the first positive late-stage trial for an mRNA cancer vaccine and sent Moderna shares up more than 120%, the companies said.
- On Wednesday, Moderna and Merck announced their personalized mRNA vaccine intismeran combined with Keytruda met primary and secondary endpoints in a Phase 3 trial of 1,137 high-risk melanoma patients.
- Designed to target unique mutations in each patient's tumor, intismeran trains the immune system to identify and destroy remaining cancer cells as an adjuvant therapy administered after surgery.
- Shares of Moderna surged 93% on Wednesday after the vaccine-plus-Keytruda combination demonstrated superior efficacy in preventing melanoma recurrence and spread compared with Keytruda alone in the late-stage study.
- Merck and Moderna plan to present detailed trial results at an upcoming medical meeting and share findings with regulators, having already secured an expedited review pathway from the FDA and European Medicines Agency.
- Manufacturing each personalized dose takes six weeks, while companies explore this mRNA approach across nine additional Phase 2 and Phase 3 trials spanning melanoma, lung, bladder, kidney, pancreatic and gastric cancers.
319 Articles
319 Articles
Moderna’s skin cancer vaccine shows promise in trial
An experimental vaccine prevented the return and spread of cancer in high-risk melanoma patients, Moderna and Merck announced Wednesday, a milestone in the pursuit of cancer therapies. Built on the mRNA platform that allowed Moderna to quickly roll out COVID-19 vaccines five years ago, intismeran is a genetically personalized vaccine that instructs the patient’s immune system to attack tumors, slowing melanoma’s progression and spread. Such “neo…
The actions of the pharmaceutical companies Moderna and Merck lived a historic day on the stock market. Especially the first one that saw their actions steeped 176.97% at the close until the $174.38. The reason? Both companies announced the positive preliminary results of clinical trials of an experimental melanoma vaccine. Merck, for his part, ... Continue reading "Moderna and Merck shoot in the stock market after a successful trial of an exper…
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treatment.
A personalized vaccine against melanoma showed positive results in the final phase of clinical trials, Merck and Moderna announced
Coverage Details
Bias Distribution
- 52% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
